Author

Véronique Moreau-Mallet

Observed names: V. Moreau Mallet, V. Moreau-Mallet

Institution: Bristol-Myers Squibb (France)

Observed institutions: Janssen (France), Bristol-Myers Squibb (France)

ORCID: 0009-0002-2972-1664

Observed ORCID: 0009-0002-2972-1664

OpenAlex ID: A5019775949

Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone

2008 · P.-M. Llorca, P. Bouhours, et al. · L Encéphale · 15

L’initiation thérapeutique dans les épisodes psychotiques et maniaques : recueil des attitudes françaises par Focus Group

2012 · M. Benoit, F. Bellivier, et al. · L Encéphale · 6

Symptom control, functioning, and hospitalization status in French patients changed from oral atypical antipsychotics to risperidone long-acting injectable

2006 · Pierre-Michel Llorca, Jean-Pierre Kahn, et al. · International Journal of Psychiatry in Clinical Practice · 6

Prises en charge, besoins et attentes de patients souffrant de troubles bipolaires I (Étude ECHO – France)

2011 · S. Guillaume, P. Courtet, et al. · L Encéphale · 4

P.2.a.007 “Difficult depression” at private psychiatric clinics throughout France: an epidemiological survey (DEDICACE survey)

2006 · T. Bougerol, A. Gérard, et al. · European Neuropsychopharmacology · 1

Quality of life and care experience in durable responders to immune checkpoint inhibitors for advanced or metastatic NSCLC or melanoma

2026 · N. Girard, J. Bonastre, et al. · Immuno-Oncology Technology

Hospitalization at home use analysis for immune checkpoint inhibitors administrations in France: Care pathways, costs and development opportunities

2026 · Anne-Claire Toffart, Gaëtan Casanova, et al. · Bulletin du Cancer

153P Factors associated with acceptance and continuation of patients treated with immune checkpoint inhibitors in hospital-at-home: The SATISFACT-HOME study

2025 · N. Texier, A.C. Toffart, et al. · Immuno-Oncology Technology

Quality of Life (QoL) and care pathway in patients with durable response to Immune Checkpoint Inhibitors (ICI-DR) for advanced or metastatic melanoma: QUALICI study

2025 · C. Robert, J. Bonastre, et al. · EJC Skin Cancer

95P Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study

2024 · N. Girard, J. Bonastre, et al. · Immuno-Oncology Technology

91P Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022

2024 · A.C. Toffart, G. Casanova, et al. · Immuno-Oncology Technology

HSD46 Care Pathway of Lung Cancer and Melanoma Patients Treated With Immune Checkpoint Inhibitors (ICI) in Hospital at Home and Administration Costs in France in 2021 and 2022

2024 · AC Toffart, G Casanova, et al. · Value in Health

PCR218 Health-Related Quality of Life (HRQoL), in Patients With Durable Response to Immune Checkpoint Inhibitors (ICIS) for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma: QUALICI Study

2024 · N. Girard, C. Robert, et al. · Value in Health

Fréquence des symptômes d’allure psychotique observés chez l’adulte en consultation de médecine générale

2005 · Joël Pon, Hervé Huguel, et al. · La Presse Médicale

Works count: 14

Citation count: 32

H-index: 4

I10-index: 1